Date: 2017-02-23
Type of
information: Initiation of development program
phase: preclinical
Announcement: initiation of development program
Company: Abivax (France)
Product: antiviral molecules with potential for Dengue virus treatment
Action
mechanism:
Disease: dengue fever
Therapeutic
area: Infectious diseases
Country:
Trial
details:
Latest
news:
- • On February 23, 2017, Abivax announced that the company is currently screening its targeted library of small molecules to discover and develop antiviral therapeutic
candidates against dengue fever. The company recently discovered several molecules that are active against the virus in vitro, some of which could be developed as therapeutic drug-candidates. “The Abivax antiviral platform, which consists of a library of >1000 small molecules
targeting the modulation of viral RNA splicing, is an established tool for identifying promising antiviral
compounds. Our technology has already been validated by providing product candidates against a number
of viral diseases, including HIV and chikungunya” said Prof. Hartmut J. Ehrlich, CEO of Abivax.
Is
general: Yes
